Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26661378
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Receptors+Clin+Investig
2015 ; 2
(4
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
IL-10: Expanding the Immune Oncology Horizon
#MMPMID26661378
Chan IH
; Wu V
; McCauley S
; Grimm EA
; Mumm JB
Receptors Clin Investig
2015[]; 2
(4
): ä PMID26661378
show ga
Recent advances in immunoncology have dramatically changed the treatment options
available to cancer patients. However, the fundamental challenges with this
therapeutic modality are not new and still persist with the current wave of
immunoncology compounds. These challenges are centered on the activation and
expansion, induction of intratumoral infiltration and persistence of highly
activated, cytotoxic, tumor antigen specific CD8+ T cells. We have investigated
the anti-tumor mechanism of action of pegylated recombinant interleukin-10,
(PEG-rIL-10) both pre-clinically with murine (PEG-rMuIL-10) and now clinically
(AM0010) with human pegylated interleukin-10. The preponderance of data suggest
that IL-10's engagement of its receptor on CD8+ T cells enhances their activation
status leading to antigen specific expansion. Quantitation of CD8+ T cell tumor
infiltration reveals that treatment of both humans and mice with pegylated rIL-10
results in 3-4 fold increases of intratumoral, cytotoxic, CD8+ T cells. In
addition, mice cured of their tumors with PEG-rMuIL-10 exhibit long term
immunological protection from tumor re-challenge and long term treatment of
cancer patients with AM0010 results in the persistence of highly activated CD8+ T
cells. Cumulatively, these data suggest the IL-10 represents an emerging
therapeutic that specifically addresses the fundamental challenges of the current
wave of immunoncology assets.
free
free
free
